Potential Relevance of α1-Adrenergic Receptor Autoantibodies in Refractory Hypertension
2008

Role of α1-Adrenergic Receptor Autoantibodies in Refractory Hypertension

Sample size: 81 publication Evidence: moderate

Author Information

Author(s): Wenzel Katrin, Haase Hannelore, Wallukat Gerd, Derer Wolfgang, Bartel Sabine, Homuth Volker, Herse Florian, Hubner Norbert, Schulz Herbert, Janczikowski Marion, Lindschau Carsten, Schroeder Christoph, Verlohren Stefan, Morano Ingo, Muller Dominik N., Luft Friedrich C., Dietz Rainer, Dechend Ralf, Karczewski Peter

Primary Institution: Medical Faculty of the Charité, Franz-Volhard Clinic and HELIOS Klinikum-Berlin, Experimental and Clinical Research Center, Berlin, Germany

Hypothesis

α1-adrenergic receptor autoantibodies (α1-AAB) may play a mechanistic role in refractory hypertension and could represent a therapeutic target.

Conclusion

The study provides evidence that α1-AAB can induce signaling pathways important for hypertension and cardiac remodeling.

Supporting Evidence

  • 41 out of 81 patients with refractory hypertension had α1-AAB.
  • Immunoadsorption significantly reduced blood pressure in patients with α1-AAB.
  • Gene expression analysis showed upregulation of PLA2-IIA and Cacna1c in response to α1-AAB.
  • α1-AAB and rabbit α1-AB induced calcium signaling in cardiomyocytes.
  • Immunoadsorption led to a sustained reduction in α1-AAB activity for 180 days.

Takeaway

Some people with high blood pressure have special antibodies that can make their condition worse, but removing these antibodies can help lower their blood pressure.

Methodology

The study involved clinical and basic studies, including immunoadsorption treatments and various assays to analyze the effects of α1-AAB.

Potential Biases

The lack of a control group may introduce bias in interpreting the effects of immunoadsorption.

Limitations

The study was uncontrolled and did not include a randomized double-blind trial.

Participant Demographics

Patients with refractory hypertension requiring three or more antihypertensive medications, aged 46-81 years, with a mix of male (59%) and female (41%) participants.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0003742

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication